Heart Failurewithreducedejectionfraction
Total Page:16
File Type:pdf, Size:1020Kb
B:160 mm T:150 mm S:130 mm Congress organised by the Heart Failure Association of the ESC * ACT IVAT E THE HEART1,2 Heart Failure ACT IVAT E LIFE th ENTRESTO® keeps your and 4 World Congress symptomatic HFrEF patients living on Acute Heart Failure 3 2017 longer and out of the hospital • 20% reduced risk of CV death or fi rst HF hospitalisation vs enalapril (P<0.0001; 3† ARR=4.7%) Final Programme ENTRESTO® helps improve PARIS 4 Quality of Life • • Signifi cant improvements in Quality of Life vs enalapril, as measured by reduced deterioration of heart failure symptoms and physical limitations B:220 mm T:210 mm T:210 (P=0.001)4‡ S:190 mm 2017 When you see symptoms, IT’S TIME FOR ENTRESTO3 Failure Failure Join us and discover the world of a HFrEF patient. Please see Summary of Product Characteristics at Booth B30. Heart This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions. aris ARR=absolute risk reduction; CV=cardiovascular; HF=heart failure; HFrEF=heart failure with reduced ejection fraction. France * The complementary cardiovascular benefi ts of ENTRESTO in patients with HFrEF are attributed to the enhancement of peptides that are degraded by neprilysin, such as natriuretic peptides (NP), by sacubitril and the simultaneous inhibition of the deleterious effects of angiotensin II by valsartan. P † Primary end point. ‡ Secondary end point that measured the change from baseline to 8 months in the clinical summary score on the Kansas City Cardiomyopathy Questionnaire (KCCQ). 29 April - 2 May References: 1. Fala L. Entresto (sacubitril/valsartan): First-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure. Am Health Drug Benefi ts. 2015;8(6):330-334. 2. Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci. 2016;130(2):57-77. 3. ENTRESTO Summary of Product Characteristics. European Medicines Agency, 2016. http://www.ema.europa.eu. 4. McMurray JJ, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus Heart Failure: rendez-vous with the future enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. © 2017 Novartis Pharma AG, CH-4002 Basel March 2017 GLCM/LCZ/0228 www.escardio.org/HFA #heartfailure2017 10709397_ESC_FinalPrgrmAd_M1.indd 1 3/9/17 1:27 PM PREPARED BY FCB Releasing as: PDFX-1a Production: Barbara.Grant x3946 Job #: 10709397 Colors: 4C AD:Adam Nemser Client: Novartis Live: 130 mm w x 190 mm h AE: Lyn Settlemyre x3906 Product: Entresto Trim: 150 mm w x 210 mm h Producer: Patricia Chung x3162 Client Code: GLCM/LCZ/0228 Bleed: 160 mm w x 220 mm h QC: L. Powell Date: March 9, 2017 1:07 PM Note: Digital Artist: CL Add’l Info: Proof: M1 Fonts: NewsGoth Cn BT, The Great M1 Spellcheck: D. Fitzgerald Escape, Helvetica Neue LT Std, Minion Pro FR Spellcheck: Path: PrePress:Novartis:LCZ696:10709397:10709397_ESC_FinalPrgrmAd_M1 4C ESC Final Program Ad Harnessing a revolution in biology for human health® Alnylam is developing RNA Inteference (RNAi) therapeutics with an aim to meaningfully impact patient health. Learn more at Alnylam.com © 2016 Alnylam Pharmaceuticals, Inc. Welcome Address Dear friends and colleagues, On behalf of the board of the Heart Failure Association and the organising committee, it is our great pleasure to welcome you to our annual congress Heart Failure 2017 & World Congress on Acute Heart Failure. “Rendez-vous with the future” is the theme of this year’s meeting of the world`s leading heart failure association. Our congress is an essential platform for scientific exchange and networking with invaluable contributions of experts from around the world. The scientific programme will provide the latest updates from the field of heart failure and recommendations for implementation in daily practice. Original scientific research is the core of the congress and we are proud to report the submission of a record-breaking 2 197 abstracts & clinical cases. In addition, we are honoured that our esteemed colleagues Prof. Michel Komajda and Prof. Faiez Zannad will be awarded HFA Lifetime Achievement Awards and present the Eugene Braunwald and Philip Poole-Wilson Lectures during the Inaugural session. On Sunday, join us for the HoT Walk organised by the Heart Failure specialist of Tomorrow to raise the public awareness on heart failure. We look forward to welcoming you to beautiful Paris - the “City of Lights”. Alexandre Mebazaa Frank Ruschitzka Heart Failure 2017 Chairperson HFA President 1 Organising Committees BOARD MEMBERS OF THE HFA Frank Ruschitzka HFA President Petar Seferovic President Elect Gerasimos Filippatos Immediate Past President Andrew Coats Treasurer Mitja Lainscak National HF Societies coordinator Rudolf De Boer Chairman of the Basic Science section Massimo Piepoli Chairman of the Clinical Science section Marisa Crespo-Leiro Secretary Clinical Section Basic Science Section Ex-officio Yuri Lopatin Johann Bauersachs Marco Metra Jelena Celutkiene Johannes Backs Alexandre Mebazaa Veli Pekka Harjola Alexander Lyon Stefan Anker Ewa Jankowska Stephane Heymans Lars Lund Piotr Ponikowski Christian Mueller Isabel Bardinet Giuseppe Rosano Loreena Hill Sui Generis Davor Milicic Theresa Mcdonagh Jillian Riley Arno Hoes Local organising committee Alexandre Mebazaa - Heart Failure 2017 Chairperson Thibaud Damy Patrick Rossignol Patrick Jourdain Michel Komajda François Roubille Florence Beauvais Alain Cohen Solal Véronique Alibert Richard Isnard Jean-Yves Le Heuzey Véronique Thore Frédéric Mouquet Faiez Zannad Damien Logeart Stéphane Germain Pascal De Groote Jean-Noël Trochu Yves Juillère Michel Galinier Dominique Guedj Claire Bouleti Laribi Saïd Alain Ducardonnet Etienne Gayat 2 Mebership • Regular • Silver • Gold • Fellows VISION OF • Heart Failure Specialists of Tomorrow THE HFA • Committees and Study Groups Adocacy • National Heart Failure Societies • Heart Failure Awareness Day • Patient website • HFA Summit Research • European Journal Congresses of Heart Failure Eents • ESC Heart Failure • Heart Failure congresses • Registries • Scientific Workshops • Winter Meeting • Clinical Trialists Summer School • Joint sessions at international congresses TO REUCE THE BUREN OF Education CARIOVASCULAR ISEASE IN EUROE • E-learning • Webinars • Heart Failure Specialist Curriculum Grants • Heart Failure Certification • Nurse Research Fellowship • Postgraduate Course in Heart Failure • Congress grants & awards • Guidelines • Patient Care Workshop 3 HEART FAILURE ASSOCIATION OF THE ESC Working together for the future of heart failure ONLY DURING THE CONGRESS GET 20% OFF YOUR ANNUAL MEMBERSHIP* Make the most of your congress Relive the congress with exclusive access to slides and webcasts • Meet your peers in the HFA Members’ Lounge • Benefit from exclusive discount on Heart Failure Certification and educational courses • Find your colleagues online with the HFA members network • Join our Fellow community and get recognition from your peers SPECIAL PRICE: APPLY FOR MEMBERSHIP * * SILVER 77€ GOLD 115€ *Conditions apply: discount exclusively available during the duration of the congress. For more information come to the HFA stand B20. I’M AN HFA MEMBER. WE ARE THE ESC BOOTH B20 www.escardio.org/HFA Table of contents Congress Information ....................................................................................................................................................................................................................................8 Highlights at Heart Failure 2017 .................................................................................................................................................................................................10 Sessions by Topic ................................................................................................................................................................................................................................................. 11 Sessions by Day.......................................................................................................................................................................................................................................................17 Scientific Programme Saturday 29 April Scientific sessions .....................................................................................................................................................................................................................................22 Poster session 1 ..........................................................................................................................................................................................................................................42 Sunday 30 April Hands-On tutorials...............................................................................................................................................................................................................................72 Scientific sessions .....................................................................................................................................................................................................................................75 Poster session 2 ..........................................................................................................................................................................................................................................98